The takeaway
GeneDx Holdings Corp. shows a pronounced seasonal pattern over 6 years of data — strongest in February (+50.0%) and softest in August (−14.1%).
Right now
In July, the stock has risen 80% of years, averaging +11.9%, about +9.8 pts better than the S&P 500.
The full picture
GeneDx Holdings Corp.'s most dependable month has been February, higher in 5 of 5 years; August has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in February (+50.3 pts); it has trailed the market most in August (−14.4 pts).
“vs S&P” is GeneDx Holdings Corp.’s average for a month minus the S&P 500’s average for that same month — isolating GeneDx Holdings Corp.’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, February has closed higher 100% of the time versus 100% across the last 6 years — the pattern is holding.
Figures are the typical (median) February return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: February, up in all 5 Februaries while the other eleven tend to blur together.
Its average (+50.0%) and median (+47.0%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even February ranges by 34.6% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: February has cleared the S&P 500 by +50.3 points above the index. It bucks the broad tape, besides: February lifts just 49% of stocks across the market.
A few other months pull their weight: January, June, and July have also closed higher more often than not. On the other side of the ledger, August has been the soft spot — the weakest of 6 months that average a loss (−14.1%), and the edge isn't year-round — the stock has trailed the S&P 500 in August, March, and November. Its roughest month on record was a −60.2% November in 2022 — a reminder of how hard even a seasonal name can fall.
February has now closed higher 5 years running.
The takeaway is less about when to buy than what to expect: February aside, the stock's months offer little reliable tilt. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (February), its worst (August), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (February, +50.0%) has run well ahead of its worst (August, −14.1%) — the heatmap above shows how steady that gap has been year to year.
February has been the strongest, averaging +50.0% and closing higher in all 5 years on record since 2020.
It's the weakest, averaging −14.1% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade